Haisen Pharmaceutical: Shareholders plan to reduce their stake in the company by no more than 3%.

Hesen Pharmaceutical announced that Dongyang Taiqi Investment Management Partnership, which holds 10.78% of the shares, plans to reduce its holdings by no more than 4.57 million shares through centralized bidding and block trading within 3 months after 15 trading days. Taiqi Investment is an employee stock platform controlled by the actual controller of the company. This share reduction is for other partners of Taiqi Investment, and the actual controller of the company has promised not to participate in this share reduction.